10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $1.12 billion. The enterprise value is $809.50 million.
Important Dates
The next estimated earnings date is Tuesday, April 29, 2025, after market close.
Earnings Date | Apr 29, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 122.30 million shares outstanding. The number of shares has increased by 2.81% in one year.
Current Share Class | 108.25M |
Shares Outstanding | 122.30M |
Shares Change (YoY) | +2.81% |
Shares Change (QoQ) | +0.72% |
Owned by Insiders (%) | 8.44% |
Owned by Institutions (%) | 85.34% |
Float | 106.02M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.81 |
Forward PS | 1.81 |
PB Ratio | 1.58 |
P/TBV Ratio | 1.62 |
P/FCF Ratio | n/a |
P/OCF Ratio | 168.11 |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.33 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.12.
Current Ratio | 4.97 |
Quick Ratio | 4.09 |
Debt / Equity | 0.12 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -48,114.75 |
Financial Efficiency
Return on equity (ROE) is -25.17% and return on invested capital (ROIC) is -14.77%.
Return on Equity (ROE) | -25.17% |
Return on Assets (ROA) | -12.77% |
Return on Invested Capital (ROIC) | -14.77% |
Return on Capital Employed (ROCE) | -24.03% |
Revenue Per Employee | $467,676 |
Profits Per Employee | -$139,837 |
Employee Count | 1,306 |
Asset Turnover | 0.65 |
Inventory Turnover | 2.50 |
Taxes
In the past 12 months, 10x Genomics has paid $4.93 million in taxes.
Income Tax | 4.93M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.39% in the last 52 weeks. The beta is 1.93, so 10x Genomics's price volatility has been higher than the market average.
Beta (5Y) | 1.93 |
52-Week Price Change | -75.39% |
50-Day Moving Average | 12.18 |
200-Day Moving Average | 16.71 |
Relative Strength Index (RSI) | 33.15 |
Average Volume (20 Days) | 3,120,647 |
Short Selling Information
The latest short interest is 11.32 million, so 9.25% of the outstanding shares have been sold short.
Short Interest | 11.32M |
Short Previous Month | 8.42M |
Short % of Shares Out | 9.25% |
Short % of Float | 10.67% |
Short Ratio (days to cover) | 3.63 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $610.79 million and -$182.63 million in losses. Loss per share was -$1.52.
Revenue | 610.79M |
Gross Profit | 414.78M |
Operating Income | -192.46M |
Pretax Income | -233.22M |
Net Income | -182.63M |
EBITDA | -156.58M |
EBIT | -192.46M |
Loss Per Share | -$1.52 |
Full Income Statement Balance Sheet
The company has $393.40 million in cash and $82.61 million in debt, giving a net cash position of $310.79 million or $2.54 per share.
Cash & Cash Equivalents | 393.40M |
Total Debt | 82.61M |
Net Cash | 310.79M |
Net Cash Per Share | $2.54 |
Equity (Book Value) | 710.13M |
Book Value Per Share | 5.81 |
Working Capital | 466.75M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $6.66 million and capital expenditures -$12.39 million, giving a free cash flow of -$5.73 million.
Operating Cash Flow | 6.66M |
Capital Expenditures | -12.39M |
Free Cash Flow | -5.73M |
FCF Per Share | -$0.05 |
Full Cash Flow Statement Margins
Gross margin is 67.91%, with operating and profit margins of -31.51% and -29.90%.
Gross Margin | 67.91% |
Operating Margin | -31.51% |
Pretax Margin | -29.09% |
Profit Margin | -29.90% |
EBITDA Margin | -25.64% |
EBIT Margin | -31.51% |
FCF Margin | n/a |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.80% |
Shareholder Yield | -2.80% |
Earnings Yield | -16.30% |
FCF Yield | -0.51% |
Dividend Details Analyst Forecast
The average price target for 10x Genomics is $20.00, which is 118.34% higher than the current price. The consensus rating is "Buy".
Price Target | $20.00 |
Price Target Difference | 118.34% |
Analyst Consensus | Buy |
Analyst Count | 16 |
Revenue Growth Forecast (5Y) | 6.71% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 7.44 and a Piotroski F-Score of 5.
Altman Z-Score | 7.44 |
Piotroski F-Score | 5 |